The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1

This publication has 134 references indexed in Scilit:

• Short Communication: A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures with the Nonnucleoside Reverse Transcriptase Inhibitor Thiocarboxanilide UC-781
  AIDS Research and Human Retroviruses, 1998
• Preliminary efficacy, pharmacokinetics and safety of repeated multiple doses of MKC-442 in HIV-infected volunteers
  Antiviral Research, 1997
• HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
  Science, 1996
• Molecular modeling studies of HIV‐1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity
  Protein Science, 1995
• The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds
  Antiviral Research, 1995
• In Vitro Inhibition Of Human Immunodeficiency Virus Type 1 By A Combination Of Delavirdine (U-90152) With Protease Inhibitor U-75875 Or Interferon-
  The Journal of Infectious Diseases, 1995
• Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
  Nature, 1995
• Viral dynamics in human immunodeficiency virus type 1 infection
  Nature, 1995
• Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional Structure of HIV-1 Reverse Transcriptase
  Journal of Molecular Biology, 1994
• Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative
  Biochemical and Biophysical Research Communications, 1989